Enveric Biosciences, Inc. (ENVB)
Healthcare · NCM
Price as at 30 Sept 2026, 17:48 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
Enveric Biosciences, Inc. trades at $1.46, which is 84% below the $2.68 our fair value estimate puts on the business. On that measure alone it screens as undervalued, though a valuation model is an argument rather than a measurement, and the market is frequently right about why something is cheap.
Our moat model scores it 5 out of 100, which is little in the way of a moat. A moat is a structural reason competitors cannot take the profits away, and it matters more to a long holding period than any single quarter's numbers do.
ENVB dividend history
No individual payments are on record for this listing, so the current facts above are all we can honestly show.
About Enveric Biosciences, Inc.
Enveric Biosciences, Inc., a biotechnology company, focuses on the development of small molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders in the United States. Its lead drug candidate is EB-003, a novel derivative of DMT in preclinical development for mental health indications. The company also develops EVM401 series comprising novel phenylalkylamines and indolethylamines, as well as mescaline-derived compounds to target addiction and neuropsychiatric disorders; and Psybrary, a proprietary library. Enveric Biosciences, Inc. is headquartered in Cambridge, Massachusetts.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
ENVB passes 2 of our 30 screens today
Each screen prints the exact criteria it used, and the circumstances in which it is wrong.
ENVB peers
The largest companies in the same industry (Biotechnology), then in the same sector.
- CSLLY CSL Limited
- RVMD Revolution Medicines, Inc.
- CMXHF CSL Limited
- ALNY Alnylam Pharmaceuticals, Inc.
- RPRX Royalty Pharma plc
- INCY Incyte Corporation
- INSM Insmed Incorporated
- GNMSF Genmab A/S
Every healthcare company we cover is on the Healthcare hub.
Common questions
Is Enveric Biosciences, Inc. (ENVB) undervalued?
Against our fair value estimate of $2.68, ENVB at $1.46 is 84% below fair value. That is one model's answer, not a recommendation. It is built from normalized earning power with growth capped deliberately low, which understates companies whose value is mostly future growth.
Where does SteadyShares get its ENVB data?
Fundamentals for ENVB come from company filings and exchange data, as listed on NCM; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 30 Sept 2026, 17:48 UTC and is delayed. Our data quality score for this company is 67/100, which is the share of the inputs behind our scores that were actually available rather than assumed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for ENVB, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.